Literature DB >> 20398117

Metabolic syndrome and risk of dementia in older adults.

Paola Forti1, Nicoletta Pisacane, Elisa Rietti, Anna Lucicesare, Valentina Olivelli, Erminia Mariani, Patrizia Mecocci, Giovanni Ravaglia.   

Abstract

OBJECTIVES: To investigate the association between metabolic syndrome (MetS; a clustering of cardiovascular risk factors including abdominal obesity, hypertension, dyslipidemia, and hyperglycemia, each of which has been individually associated with dementia) and incident dementia, Alzheimer's disease (AD), and vascular dementia (VaD) in older adults before and after the age of 75.
DESIGN: Prospective population-based cohort.
SETTING: An Italian municipality. PARTICIPANTS: A community-based sample of 749 subjects aged 65 and older who, in 1999/2000, were free of cognitive impairment and, in 2003/04, underwent follow-up for incident dementia. MEASUREMENTS: The relationship between incident overall dementia, AD, and VaD and MetS. Dementia was defined according to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. MetS was defined according to the National Cholesterol Education Program criteria.
RESULTS: Risk of overall dementia and its subtypes was not associated with MetS or any MetS component in participants younger than 75. In participants aged 75 and older, MetS was associated with a lower risk of AD (hazard ratio (HR)=0.33, 95% confidence interval (CI)=0.12-0.94) but not of VaD, and abdominal obesity was associated with a lower risk of overall dementia (HR=0.53, 95% CI=0.28-0.98).
CONCLUSION: MetS measured in late life is not associated with risk of dementia. After age 75, persons with MetS may even be at lower risk for AD.

Entities:  

Mesh:

Year:  2010        PMID: 20398117     DOI: 10.1111/j.1532-5415.2010.02731.x

Source DB:  PubMed          Journal:  J Am Geriatr Soc        ISSN: 0002-8614            Impact factor:   5.562


  27 in total

1.  Rosiglitazone monotherapy in mild-to-moderate Alzheimer's disease: results from a randomized, double-blind, placebo-controlled phase III study.

Authors:  Michael Gold; Claire Alderton; Marina Zvartau-Hind; Sally Egginton; Ann M Saunders; Michael Irizarry; Suzanne Craft; Gary Landreth; Ulla Linnamägi; Sharon Sawchak
Journal:  Dement Geriatr Cogn Disord       Date:  2010-08-21       Impact factor: 2.959

2.  Metabolic syndrome and cognitive decline among the oldest old in Okinawa: in search of a mechanism. The KOCOA Project.

Authors:  Yuriko Katsumata; Hidemi Todoriki; Yasushi Higashiuesato; Shotoku Yasura; D Craig Willcox; Yusuke Ohya; Bradley J Willcox; Hiroko H Dodge
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2011-10-20       Impact factor: 6.053

Review 3.  Current and emerging drug treatment options for Alzheimer's disease: a systematic review.

Authors:  Nathan Herrmann; Sarah A Chau; Ida Kircanski; Krista L Lanctôt
Journal:  Drugs       Date:  2011-10-22       Impact factor: 9.546

Review 4.  The association between blood pressure and incident Alzheimer disease: a systematic review and meta-analysis.

Authors:  Melinda C Power; Jennifer Weuve; Joshua J Gagne; Matthew B McQueen; Anand Viswanathan; Deborah Blacker
Journal:  Epidemiology       Date:  2011-09       Impact factor: 4.822

Review 5.  Defining the Relationship Between Hypertension, Cognitive Decline, and Dementia: a Review.

Authors:  Keenan A Walker; Melinda C Power; Rebecca F Gottesman
Journal:  Curr Hypertens Rep       Date:  2017-03       Impact factor: 5.369

6.  C-reactive protein and familial risk for dementia: a phenotype for successful cognitive aging.

Authors:  Jeremy M Silverman; James Schmeidler; Michal S Beeri; Clive Rosendorff; Mary Sano; Hillel T Grossman; José R Carrión-Baralt; Irina N Bespalova; Rebecca West; Vahram Haroutunian
Journal:  Neurology       Date:  2012-08-15       Impact factor: 9.910

Review 7.  Mood disorders and obesity: understanding inflammation as a pathophysiological nexus.

Authors:  Joanna K Soczynska; Sidney H Kennedy; Hanna O Woldeyohannes; Samantha S Liauw; Mohammad Alsuwaidan; Christina Y Yim; Roger S McIntyre
Journal:  Neuromolecular Med       Date:  2010-12-17       Impact factor: 3.843

8.  Metabolic syndrome and cognitive decline in early Alzheimer's disease and healthy older adults.

Authors:  Amber S Watts; Natalia Loskutova; Jeffrey M Burns; David K Johnson
Journal:  J Alzheimers Dis       Date:  2013       Impact factor: 4.472

9.  Brain aging and dementia during the transition from late adulthood to old age: design and methodology of the "Invece.Ab" population-based study.

Authors:  Antonio Guaita; Mauro Colombo; Roberta Vaccaro; Silvia Fossi; Silvia Francesca Vitali; Gianluigi Forloni; Letizia Polito; Annalisa Davin; Virginia Valeria Ferretti; Simona Villani
Journal:  BMC Geriatr       Date:  2013-09-24       Impact factor: 3.921

10.  Late-life metabolic syndrome prevents cognitive decline among older men aged 75 years and over: one-year prospective cohort study.

Authors:  C-L Liu; M-H Lin; L-N Peng; L-K Chen; C-T Su; L-K Liu; L-Y Chen
Journal:  J Nutr Health Aging       Date:  2013       Impact factor: 4.075

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.